IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 1, January 2025

Optimizing Seizure Control through Combination Therapy in Epilepsy

Miss. Nandini M. Kashikar[1], Mr. Amey S. Ingole[2], Miss. Sneha V. Pawar[3], Mr. Akash P. Dhoke[4], Dr. Manisha D. Kitukale[5]
Student, Department of Pharmaceutics[1,2,3]
Assistant Professor, Department of Pharmaceutics[4]
Principal, P. Wadhwani College of Pharmacy, Yavatmal, India[5]
P. Wadhwani College of Pharmacy, Yavatmal, India[1-4]

Abstract: *Combination therapy has emerged as a vital strategy for enhancing treatment outcomes and improving the quality of life for individuals with epilepsy. This approach involves administering multiple antiepileptic drugs (AEDs) simultaneously to achieve better seizure control, improved efficacy, and reduced side effects. Research has shown that certain AED combinations, such as valproate, exhibit remarkable synergy, producing supra-additive anticonvulsant effects. However, careful risk-benefit assessments are necessary to mitigate potential increased side effects. This review highlights the benefits and challenges of combination therapy in epilepsy, discusses the mechanisms of action of various AED combinations, and explores the potential for personalized medicine approaches to optimize seizure control and improve patient outcomes.*

Keywords: Seizure, Antiepileptic, combination therapy

I. INTRODUCTION

Combination drug therapy, also known as polypharmacy or combination therapy, is a medical treatment approach that involves administering multiple drugs or therapies simultaneously to achieve better patient outcomes, improved efficacy, and reduced side effects.[1] This approach is commonly used to manage complex diseases such as HIV, cancer, hypertension, and diabetes, where a single drug may not be sufficient to control the condition. the concept of combination therapy. When we use multiple therapeutic agents together, we can create a synergistic effect that enhances treatment outcomes. This is particularly important in cancer treatment, where a single drug may not be enough to combat the disease.[2]

To achieve this, we need to develop new drug delivery systems that can accommodate multiple agents. This involves several challenges:

1. Engineering existing systems: We need to modify existing drug delivery systems to accommodate multiple agents.
2. Synthesizing new materials: We require new materials that can be used to create multi-agent delivery systems.
3. Designing carriers with new structures: We need to design carriers that can deliver multiple agents in a controlled and coordinated manner.

By overcoming these challenges, we can create innovative drug delivery systems that meet the requirements of combination therapy. This can lead to improved treatment outcomes, enhanced patient care, and better management of complex diseases like cancer, AIDS, migraines.[3]

1.1 How the combinational drugs can deploy in body

Cancer treatment is shifting from using one drug to target one area to using multiple drugs to target many areas, but this approach faces challenges like dissimilar pharmacokinetics and tissue distribution, leading to serious side effects. Nanoparticles have emerged as a promising solution, carrying multiple drugs to the tumour site, improving treatment outcomes, reducing side effects, and enabling personalized treatment. The "two-in-one" approach, packaging.

multiple drugs in a single nanoparticle, provides beneficial overlapping pharmacological profiles, reduced toxicity, and radiometric drug delivery. Additionally, RNAi-based co-delivery platforms have shown promise in treating drug-

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 1, January 2025

resistant tumors, and these emerging strategies may revolutionize cancer treatment, offering improved pharmacological control and personalized treatment options.[4]

1.2 Benefits of combinational therapy

- **Cancer treatment**: -The combination of two or more therapeutic treatments to specifically target cancer-inducing or cell-sustaining pathways is a cornerstone of cancer therapy.[5]
- **Blood pressure reduction**: -Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects. The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.
- **HIV/AIDS Treatment**: Combination antiretroviral therapy (cART) is the standard of care for HIV-infected patients.
- **Tuberculosis Treatment**: Combination therapy is essential for treating tuberculosis, as it helps prevent the emergence of drug-resistant strains.
- **Cardiovascular Disease**: Combinations of antihypertensive, antidiabetic, and lipid-lowering agents are often used to manage cardiovascular risk factors.
- **Convulsion**: a combination of two or more anti-epileptic drugs (AEDs) may be required to improve efficacy (seizure control) and tolerability. Polytherapy (treatment with two or more AEDs) can affect efficacies.[6]

II. TRADITIONAL APPROACH TO EPILEPSY RESISTANCE

Traditional antiseizure medications (ASMs) have long been the cornerstone of epilepsy management, providing substantial benefits to a significant proportion of patients. By modulating neuronal excitability, these conventional medications effectively inhibit the abnormal electrical activity that precipitates seizures. The development of ASMs has transformed epilepsy treatment, enabling numerous individuals to achieve seizure control and experience improved quality of life. Various classes of ASMs are available, each targeting specific mechanisms involved in seizure generation and propagationA substantial proportion of patients, approximately one-third, do not respond adequately to traditional ASMs, leading to treatment-resistant epilepsy. This phenomenon poses a significant clinical challenge, emphasizing the need for novel therapeutic approaches to address this unmet medical need.

2.1 Challenges in achieving seizure control with traditional therapies

The quest for effective seizure control remains an elusive goal for many individuals with epilepsy, particularly those with drug-resistant forms of the condition. Traditional therapies, although beneficial for some, often fall short in providing adequate seizure control, leaving patients to contend with recurrent seizures that profoundly impact their daily lives. The inherent complexity of epilepsy, characterized by its heterogeneous nature, diverse underlying causes, and varied responses to treatment, poses a significant barrier to developing effective therapies. As a result, traditional antiseizure medications (ASMs) frequently fail to provide uniform seizure control, as their efficacy can vary greatly from person to person due to differences in brain structure and function. This variability underscores the need for personalized therapeutic approaches that take into account the unique characteristics of each individual's epilepsy.

2.2 Need for treatment approach for epilepsy management

The ongoing struggle to manage drug-resistant epilepsy underscores the urgent need for novel and innovative treatment strategies. To address this challenge, researchers have intensified their efforts to develop therapies that cater to specific epilepsy subtypes, uncover new drug targets, and explore non-pharmacological interventions. Recent advances in technology, coupled with a deeper understanding of epilepsy's complex mechanisms, have opened up new avenues for groundbreaking therapeutic approaches. For instance, neurostimulation devices, such as RNS, VNS, and DBS, offer promising alternatives for patients who have not responded to traditional ASMs. Moreover, the emerging fields of precision medicine and personalized treatment approaches hold great promise for tailoring therapies to individual patients based on their unique genetic and molecular profiles. Additionally, gene therapies are being explored as

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 1, January 2025

potential treatments for specific genetic epilepsy syndromes, offering new hope for patients and families affected by these debilitating conditions.[7]

III. COMBINATIONAL DRUG THERAPY USED IN TREATMENT OF EPILEPSY

The paradigm shift in epilepsy treatment is driven by the recognition that a substantial proportion of patients do not achieve adequate seizure control with traditional monotherapy. As a result, combination therapy has emerged as a vital strategy for enhancing treatment outcomes and improving the quality of life for individuals with epilepsy. While monotherapy remains the first line of defence, the judicious use of combination therapy can provide improved seizure control, reduced side effects, and enhanced patient satisfaction.[8]

Research has shown that combining two or three antiepileptic medications can be an effective approach for patients who have failed to respond to monotherapy. However, the optimal combination therapy regimen remains unclear, and further research is necessary to inform evidence-based guidelines. Key areas of investigation include the optimal timing of combination therapy initiation, the selection of medications with complementary mechanisms of action, and the determination of optimal dosing strategies.

Moreover, the development of novel antiepileptic medications with improved efficacy and tolerability profiles has expanded the range of treatment options available for combination therapy. The increasing recognition of the importance of personalized medicine in epilepsy treatment also underscores the need for tailored combination therapy approaches that take into account individual patient characteristics, seizure types, and comorbidities.[9]

Ultimately, the goal of combination therapy in epilepsy is to achieve optimal seizure control while minimizing adverse effects and improving patient outcomes. By continuing to advance our understanding of the complex mechanisms underlying epilepsy and the interactions between different antiepileptic medications, we can develop more effective and personalized combination therapy regimens that improve the lives of individuals with epilepsy.[10]

3.1 Mechanism Of Action of Combinational Therapy in Epilepsy

Anticonvulsant medications can be broadly classified into three distinct categories based on their mechanisms of action. The first category comprises drugs that mitigate sustained repetitive firing, a hallmark of seizure activity, by modulating sodium channels, glutamate receptors, or voltage-dependent calcium channels. This class of drugs has demonstrated efficacy in preventing partial and generalized tonic-clonic seizures.[11] In contrast, the second category encompasses drugs that augment GABAergic neurotransmission, which can have far-reaching consequences depending on the specific site of action and receptor subtype targeted. While enhanced GABAergic activity can be beneficial in certain contexts, it can also exacerbate specific seizure types, underscoring the complexity of this mechanism. Lastly, the third category includes drugs that selectively block T-type calcium channels in thalamocortical relay cells, thereby exerting a therapeutic effect on generalized absence seizures.[12]

IV. CONCLUSION

The quest for optimal antiepileptic drug (AED) combinations has yielded promising results in experimental studies, but translating these findings to clinical practice requires caution. Despite this, certain combinations, such as valproate and lamotrigine, have shown remarkable synergy in animal models, producing supra-additive anticonvulsant effects that have been corroborated by encouraging results in human studies. However, these benefits may be offset by increased side effects, underscoring the need for careful risk-benefit assessments. In the clinical arena, levetiracetam and topiramate have emerged as standout add-on therapies for partial and certain generalized epilepsies, offering new hope for patient's refractory to traditional treatments. As research continues to unravel the complexities of AED interactions, clinicians can expect to uncover novel combination strategies that optimize seizure control while minimizing adverse effects.

V. ACKNOWLEDGMENT

We would like to extend sincere gratitude to the following individuals and organizations for their invaluable contributions to this article review:

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 5, Issue 1, January 2025

To the numerous researchers and scientists whose pioneering work in the field of combinational drug therapy for epilepsy has paved the way for this review.
To the patients and families affected by epilepsy, whose courage and resilience inspire continued efforts to improve treatment options and quality of life.
We also grateful for the support and encouragement received from colleagues, peers, and loved ones throughout the preparation of this manuscript.

REFERENCES

[1]. Quanyin Hub, Wujin Sun, Chao Wang, Zhen Gube ; Recent advances of cocktail chemotherapy by combination drug delivery systems; 2016;98 ; 19-34.
[2]. Luciano A.L., Shorvon S.D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol. 2007 Oct; 62:375–381. doi: 10.1002/ana.21064.
[3]. Hongbin Zhang, Guojie Wang & Huai Yang; Drug delivery systems for differential release in combination therapy;2011;8(2);171-190.
[4]. Suresh Gadde; multi-drug delivery nanocarriers for combination therapy;2015; Issue 11.
[5]. Reza Bayat Mokhtari 4, Tina S Homayouni, Narges Batuen Evgeniva Morgatskave, Sushil Kumar Bikul; Combination therapy in combating cancer;2017;8(23).
[6]. David S. Wald MD, Malcolm Law FRCP, Joan K. Morris PhD, Janathan P. Bestwick MSc,Nicholas J. Wald FRS; Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials;2009;11(9).
[7]. Shampa Ghosh Jitendra Kumar Sinha Soumya GhoshHitaishi Sharma Rakesh Bhaskar Kannan Badri Narayanan;A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management ;2023;13{9};1305
[8]. Stephen L.J., Brodie M.J. Seizure freedom with more than one antiepileptic drug. Seizure. 2002 Sep; 11:349–351. doi: 10.1053/seiz.2002.0711.
[9]. Abou-Khalil B. Selecting rational drug combinations in epilepsy. CNS Drugs. 2017 Oct; 31:835–844. doi: 10.1007/s40263-017-0471-7.
[10]. Charles L. P. Deckers, †Stanislaw J. Czuczwar, Yechiel A. Hekster, Antoine Keyser.Hana Kubova, Harry Meinardi, Philip N. Patsalos, Willy O. Renier, and Clementina M. Van Rijn; Selection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed;2000;41(11);1364-1374.
[11]. Kwan P., Brodie M.J. Combination therapy in epilepsy: when and what to use. Drugs. 2006; 66:1817–1829. doi: 10.2165/00003495-200666140-00004.
[12]. Ehsan M. Sarhan, Matthew C. Walker, Caroline Selai;Evidence for Efficacy of Combination of Antiepileptic Drugs in Treatment of Epilepsy;2015;5(6):267-276